NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: Implications for tumor growth retardation and docetaxel sensitivity

Free Radical Biology and Medicine

Volumn 52, Issue 9, 2012, Pages 1773-1785

  Manandhar, Sarala ^a   Choi, Bo Hyun ^a   Jung, Kyeong Ah ^b   Ryoo, In Geun ^a   Song, Mingu ^a   Kang, Su Jin ^c   Choi, Han Gon ^d   Kim, Jung Ae ^a   Park, Pil Hoon ^a   Kwak, Mi Kyoung ^b  

^a Yeungnam University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Daegu Haany University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

Breast cancer; Docetaxel; ErbB2; Free radicals; Interfering RNA; NRF2; Ovarian cancer

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE B; PROTEIN P27; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENVIRONMENTAL STRESS; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; GLUTATHIONE; HUMANS; MICE; NF-E2-RELATED FACTOR 2; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859029752     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.02.031     Document Type: Article

References (64)

1. K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, M. Yamamoto, and Y. Nabeshima An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements Biochem. Biophys. Res. Commun. 236 1997 313 322
2. M. Kobayashi, and M. Yamamoto Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation Antioxid. Redox Signal. 7 2005 385 394
3. K.I. Tong, A. Kobayashi, F. Katsuoka, and M. Yamamoto Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism Biol. Chem. 387 2006 1311 1320
4. K.I. Tong, B. Padmanabhan, A. Kobayashi, C. Shang, Y. Hirotsu, S. Yokoyama, and M. Yamamoto Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response Mol. Cell. Biol. 27 2007 7511 7521
5. M.K. Kwak, and T.W. Kensler Targeting NRF2 signaling for cancer chemoprevention Toxicol. Appl. Pharmacol. 244 2010 66 76
6. W. Li, and A.N. Kong Molecular mechanisms of Nrf2-mediated antioxidant response Mol. Carcinog. 48 2009 91 104
7. W.O. Osburn, and T.W. Kensler Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults Mutat. Res. 659 2008 31 39
8. J.D. Hayes, and M. McMahon NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer Trends Biochem. Sci. 34 2009 176 188
9. P. Nioi, and T. Nguyen A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity Biochem. Biophys. Res. Commun. 362 2007 816 821
10. T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, M. Ohtsuji, T. Suzuki, A. Kobayashi, J. Yokota, T. Sakiyama, T. Shibata, M. Yamamoto, and S. Hirohashi Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth Cancer Res. 68 2008 1303 1309
11. B. Padmanabhan, K.I. Tong, T. Ohta, Y. Nakamura, M. Scharlock, M. Ohtsuji, M.I. Kang, A. Kobayashi, S. Yokoyama, and M. Yamamoto Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer Mol. Cell 21 2006 689 700
12. T. Shibata, A. Kokubu, M. Gotoh, H. Ojima, T. Ohta, M. Yamamoto, and S. Hirohashi Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer Gastroenterology 135 2008 1358 1368 1368 e1351-1354
13. T. Shibata, T. Ohta, K.I. Tong, A. Kokubu, R. Odogawa, K. Tsuta, H. Asamura, M. Yamamoto, and S. Hirohashi Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy Proc. Natl Acad. Sci. USA 105 2008 13568 13573
14. A. Singh, V. Misra, R.K. Thimmulappa, H. Lee, S. Ames, M.O. Hoque, J.G. Herman, S.B. Baylin, D. Sidransky, E. Gabrielson, M.V. Brock, and S. Biswal Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer PLoS Med. 3 2006 e420
15. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 2001 127 137
16. D. Graus-Porta, R.R. Beerli, J.M. Daly, and N.E. Hynes ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J. 16 1997 1647 1655
17. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Look, D.L. Clarke-Pearson, and M. Davidson Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
18. U. Vaishampayan, R.E. Parchment, B.R. Jasti, and M. Hussain Taxanes: an overview of the pharmacokinetics and pharmacodynamics Urology 54 1999 22 29
19. J. Baselga, L. Norton, J. Albanell, Y.M. Kim, and J. Mendelsohn Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Res. 58 1998 2825 2831
20. D. Yu, and M.C. Hung Role of erbB2 in breast cancer chemosensitivity Bioessays 22 2000 673 680
21. D. Yu, B. Liu, M. Tan, J. Li, S.S. Wang, and M.C. Hung Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms Oncogene 13 1996 1359 1365
22. N. Wakabayashi, A.T. Dinkova-Kostova, W.D. Holtzclaw, M.I. Kang, A. Kobayashi, M. Yamamoto, T.W. Kensler, and P. Talalay Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers Proc. Natl Acad. Sci. USA 101 2004 2040 2045
23. G.S. Shim, S. Manandhar, D.H. Shin, T.H. Kim, and M.K. Kwak Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway Free Radic. Biol. Med. 47 2009 1619 1631
24. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
25. J. Carmichael, W.G. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing Cancer Res. 47 1987 936 942
26. S. Manandhar, S. Lee, and M.K. Kwak Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells Arch. Pharm. Res. 33 2010 717 726
27. J.D. Dignam, R.M. Lebovitz, and R.G. Roeder Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei Nucleic Acids Res. 11 1983 1475 1489
28. O.W. Griffith Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine Anal. Biochem. 106 1980 207 212
29. P. Zhang, A. Singh, S. Yegnasubramanian, D. Esopi, P. Kombairaju, M. Bodas, H. Wu, S.G. Bova, and S. Biswal Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth Mol. Cancer Ther. 9 2010 336 346
30. M.K. Kwak, K. Itoh, M. Yamamoto, T.R. Sutter, and T.W. Kensler Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1,2-dimethiole-3-thione Mol. Med. 7 2001 135 145
31. P. Moi, K. Chan, I. Asunis, A. Cao, and Y.W. Kan Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the β-globin locus control region Proc. Natl Acad. Sci. USA 91 1994 9926 9930
32. H.A. Lane, I. Beuvink, A.B. Motoyama, J.M. Daly, R.M. Neve, and N.E. Hynes ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency Mol. Cell. Biol. 20 2000 3210 3223
33. A.E. Lenferink, D. Busse, W.M. Flanagan, F.M. Yakes, and C.L. Arteaga ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways Cancer Res. 61 2001 6583 6591
34. H.Y. Yang, B.P. Zhou, M.C. Hung, and M.H. Lee Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27 J. Biol. Chem. 275 2000 24735 24739
35. L. Delacroix, D. Begon, G. Chatel, P. Jackers, and R. Winkler Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells DNA Cell Biol. 24 2005 582 594
36. M. Grooteclaes, D. Vernimmen, S. Plaza, F. Pasleau, D. Hodzic, and R. Winkler-Gol A new cis element is involved in the HER2 gene overexpression in human breast cancer cells Cancer Res. 59 1999 2527 2531
37. Y. de Launoit, J.L. Baert, A. Chotteau-Lelievre, D. Monte, L. Coutte, S. Mauen, V. Firlej, C. Degerny, and K. Verreman The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis Biochim. Biophys. Acta 1766 2006 79 87
38. T. Zuo, L. Wang, C. Morrison, X. Chang, H. Zhang, W. Li, Y. Liu, Y. Wang, X. Liu, M.W. Chan, J.Q. Liu, R. Love, C.G. Liu, V. Godfrey, R. Shen, T.H. Huang, T. Yang, B.K. Park, C.Y. Wang, P. Zheng, and Y. Liu FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene Cell 129 2007 1275 1286
39. H.K. Choi, J.W. Yang, and K.W. Kang Bifunctional effect of resveratrol on the expression of ErbB2 in human breast cancer cell Cancer Lett. 242 2006 198 206
40. R. Nimmanapalli, C.L. Perkins, M. Orlando, E. O'Bryan, D. Nguyen, and K.N. Bhalla Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels Cancer Res. 61 2001 759 763
41. Y.R. Kim, J.E. Oh, M.S. Kim, M.R. Kang, S.W. Park, J.Y. Han, H.S. Eom, N.J. Yoo, and S.H. Lee Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin J. Pathol. 220 2010 446 451
42. J.M. Cho, S. Manandhar, H.R. Lee, H.M. Park, and M.K. Kwak Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance Cancer Lett. 260 2008 96 108
43. A. Singh, S. Boldin-Adamsky, R.K. Thimmulappa, S.K. Rath, H. Ashush, J. Coulter, A. Blackford, S.N. Goodman, F. Bunz, W.H. Watson, E. Gabrielson, E. Feinstein, and S. Biswal RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy Cancer Res. 68 2008 7975 7984
44. X.J. Wang, Z. Sun, N.F. Villeneuve, S. Zhang, F. Zhao, Y. Li, W. Chen, X. Yi, W. Zheng, G.T. Wondrak, P.K. Wong, and D.D. Zhang Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 Carcinogenesis 29 2008 1235 1243
45. S.K. Muthuswamy, D. Li, S. Lelievre, M.J. Bissell, and J.S. Brugge ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini Nat. Cell Biol. 3 2001 785 792
46. T. Holbro, G. Civenni, and N.E. Hynes The ErbB receptors and their role in cancer progression Exp. Cell Res. 284 2003 99 110
47. J. Liang, J. Zubovitz, T. Petrocelli, R. Kotchetkov, M.K. Connor, K. Han, J.H. Lee, S. Ciarallo, C. Catzavelos, R. Beniston, E. Franssen, and J.M. Slingerland PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest Nat. Med. 8 2002 1153 1160
48. I. Shin, F.M. Yakes, F. Rojo, N.Y. Shin, A.V. Bakin, J. Baselga, and C.L. Arteaga PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization Nat. Med. 8 2002 1145 1152
49. D.B. Agus, R.W. Akita, W.D. Fox, G.D. Lewis, B. Higgins, P.I. Pisacane, J.A. Lofgren, C. Tindell, D.P. Evans, K. Maiese, H.I. Scher, and M.X. Sliwkowski Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell 2 2002 127 137
50. A. Allouche, G. Nolens, A. Tancredi, L. Delacroix, J. Mardaga, V. Fridman, R. Winkler, J. Boniver, P. Delvenne, and D.Y. Begon The combined immunodetection of AP-2α and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors Breast Cancer Res. 10 2008 R9
51. D. Yu, T. Jing, B. Liu, J. Yao, M. Tan, T.J. McDonnell, and M.C. Hung Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase Mol. Cell 2 1998 581 591
52. D. Yu, B. Liu, T. Jing, D. Sun, J.E. Price, S.E. Singletary, N. Ibrahim, G.N. Hortobagyi, and M.C. Hung Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol Oncogene 16 1998 2087 2094
53. M.N. Bijman, M.P. van Berkel, M. Kok, M.L. Janmaat, and E. Boven Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines Anticancer Drugs 20 2009 450 460
54. J.L. Merlin, M. Barberi-Heyob, and N. Bachmann In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines Ann. Oncol. 13 2002 1743 1748
55. C.X. Geng, Z.C. Zeng, and J.Y. Wang Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis World J. Gastroenterol. 9 2003 696 700
56. D.X. Cao, B. Qiao, Z.Q. Ge, and Y.J. Yuan Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel Cancer Lett. 214 2004 103 113
57. T. Jiang, N. Chen, F. Zhao, X.J. Wang, B. Kong, W. Zheng, and D.D. Zhang High levels of Nrf2 determine chemoresistance in type II endometrial cancer Cancer Res. 70 2010 5486 5496
58. G.M. DeNicola, F.A. Karreth, T.J. Humpton, A. Gopinathan, C. Wei, K. Frese, D. Mangal, K.H. Yu, C.J. Yeo, E.S. Calhoun, F. Scrimieri, J.M. Winter, R.H. Hruban, C. Iacobuzio-Donahue, S.E. Kern, I.A. Blair, and D.A. Tuveson Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis Nature 475 2011 106 109
59. K.E. Longva, N.M. Pedersen, C. Haslekas, E. Stang, and I.H. Madshus Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2 Int. J. Cancer 116 2005 359 367
60. G. Yang, J.A. Thompson, B. Fang, and J. Liu Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer Oncogene 22 2003 5694 5701
61. A. Singh, M. Bodas, N. Wakabayashi, F. Bunz, and S. Biswal Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance Antioxid. Redox Signal. 13 2010 1627 1637
62. S.A. Rushworth, K.M. Bowles, and D.J. MacEwan High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors Cancer Res. 71 2011 1999 2009
63. T.H. Kim, E.G. Hur, S.J. Kang, J.A. Kim, D. Thapa, Y.M. Lee, S.K. Ku, Y. Jung, and M.K. Kwak NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α Cancer Res. 71 2011 2260 2275
64. T. Shibata, S. Saito, A. Kokubu, T. Suzuki, M. Yamamoto, and S. Hirohashi Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway Cancer Res. 70 2010 9095 9105